Cingulate (CING) reported that as of December 31, 2024, the company had approximately $12.2M in cash and cash equivalents, a $12.1M increase from December 31, 2023, providing the company with an extended cash runway into Q4 2025, beyond its targeted submission of the NDA for CTx-1301.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Promising Prospects for Cingulate Inc.: Buy Rating Backed by Positive Phase 3 Results and Market Potential of CTx-1301
- Cingulate, Inc. (CING) Q4 Earnings Cheat Sheet
- Cingulate Inc. Advances Towards FDA Approval for CTx-1301
- Cingulate reports safety results from final Phase 3 trials for CTx-1301
- Cingulate price target adjusted to $20 from $8 at H.C. Wainwright